Update on infantile hemangiomas

Area of Science:

• Pediatric Oncology
• Dermatology
• Vascular Anomalies

Background:

• Infantile hemangiomas are the most common tumors in infants.
• The discovery of propranolol's efficacy has transformed treatment and prognosis.
• Treatment indications have expanded beyond vital organ compromise to include cosmetic outcomes.

Purpose of the Study:

• To review current concepts in infantile hemangioma management.
• To discuss pathogenesis, segmental hemangiomas, hepatic hemangiomas, and beta-blocker use.
• To highlight the impact of propranolol on infantile hemangioma care.

Main Methods:

• Review of current literature on infantile hemangiomas.
• Synthesis of information on pathogenesis and treatment strategies.
• Analysis of expanded treatment indications for infantile hemangiomas.

Main Results:

• Propranolol has significantly improved cosmetic outcomes and overall prognosis.
• Expanded indications now consider potential cosmetic deformities post-involution.
• Understanding of pathogenesis and systemic associations has advanced.

Conclusions:

• Propranolol represents a paradigm shift in infantile hemangioma management.
• Comprehensive management now includes functional and cosmetic considerations.
• Further research into pathogenesis and targeted therapies is ongoing.